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ABSTRACT
Mucopolysaccharidosis type IIIC (MPSIIIC) is a severe lysosomal
storage disease caused by deficiency in activity of the transmembrane
enzyme heparan-α-glucosaminide N-acetyltransferase (HGSNAT)
that catalyses the N-acetylation of α-glucosamine residues of
heparan sulfate. Enzyme deficiency causes abnormal substrate
accumulation in lysosomes, leading to progressive and severe
neurodegeneration, somatic pathology and early death. There is no
cure for MPSIIIC, and development of new therapies is challenging
because of the unfeasibility of cross-correction. In this study, we
generated a new mouse model of MPSIIIC by targeted disruption of
the Hgsnat gene. Successful targeting left LacZ expression under
control of the Hgsnat promoter, allowing investigation into sites of
endogenous expression, which was particularly prominent in the
CNS, but was also detectable in peripheral organs. Signs of CNS
storage pathology, including glycosaminoglycan accumulation,
lysosomal distension, lysosomal dysfunction and neuroinflammation
were detected in 2-month-old animals and progressed with age.
Glycosaminoglycan accumulation and ultrastructural changes were
also observed in most somatic organs, but lysosomal pathology
seemed most severe in liver. Furthermore, HGSNAT-deficient mice
had altered locomotor and exploratory activity and shortened lifespan.
Hence, this animal model recapitulates human MPSIIIC and provides
a useful tool for the study of disease physiopathology and the
development of new therapeutic approaches.
KEY WORDS: Lysosomal storage disease, MPSIIIC, HGSNAT,
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INTRODUCTION
Mucopolysaccharidosis type III, or Sanfilippo syndrome,
encompasses a group of rare lysosomal storage diseases (LSDs)
inherited in an autosomal recessive manner and caused by mutations
in any of the enzymes specifically involved in the catabolism of the
glycosaminoglycan (GAG) heparan sulfate (HS) (Valstar et al., 2008),
leading to the accumulation of HS in lysosomes of cells of all tissues
and organs. Sanfilippo syndrome is classified into four different
subtypes based on the deficient enzyme: MPSIIIA (OMIM#252900)
is caused by N-sulfoglucosamine sulfohydrolase (EC 3.10.1.1)
deficiency (Kresse and Neufeld, 1972); MPSIIIB (OMIM#252920)
by α-N-acetylglucosaminidase (EC 3.2.1.50) deficiency (von Figura
and Kresse, 1972); MPSIIIC (OMIM#252930) by heparan-α-
glucosaminide N-acetyltransferase (HGSNAT, EC 2.3.1.78)
deficiency (Klein et al., 1978); and MPSIIID (OMIM#252940) is
the result of N-acetyl-glucosamine-6-sulfatase (EC 3.1.6.14)
deficiency (Kresse et al., 1980). MPSIIIA is the most common type
of Sanfilippo syndrome in north-west Europe and Australia, and type
B is the most frequent type in south-east Europe and Brazil, whereas
MPSIIIC and D seem to be much rarer (Coelho et al., 1997; Meikle
et al., 1999; Valstar et al., 2008).
All subtypes of Sanfilippo syndrome show similar clinical
symptoms, and manifest primarily as progressive
neurodegenerative diseases, but MPSIIIC seems to have a milder
clinical course although the severity of the disease is highly
variable, even within families (Delgadillo et al., 2013; Héron et al.,
2011; Ruijter et al., 2008; van de Kamp et al., 1981). After a few
months of normal growth, developmental delay and behavioral
problems appear as the first signs and symptoms in affected
individuals (Héron et al., 2011; Malm and Månsson, 2010; Ruijter
et al., 2008). Later on, the disease slowly progresses to neurological
deterioration characterized by loss of speech that precedes loss of
motor function (Delgadillo et al., 2013; Héron et al., 2011; Malm
and Månsson, 2010; Ruijter et al., 2008). During this period,
affected individuals show severe behavioral problems with
hyperactivity that worsens as a result of sleep disturbances
(Delgadillo et al., 2013; Malm and Månsson, 2010; Ruijter et al.,
2008). Somatic disease in MPSIIIC, although mild, is characterized
by a wide range of clinical manifestations such as recurrent ear-
nose-throat infections, diarrhea, mild facial dysmorphisms and
visceral organomegaly, such as mild hepatomegaly (Delgadillo
et al., 2013; Héron et al., 2011; Ruijter et al., 2008). The largest
study on a cohort of individuals with MPSIIIC performed to date
was carried out in the Netherlands and showed longer survival for
Sanfilippo syndrome subtype C than for subtypes A or B, with
death occurring at a median age of 34 years, ranging from 25 to 48
(Ruijter et al., 2008). These data are supported by another study in
a smaller cohort from France in which individuals with MPSIIIC
lived significantly longer than individuals affected by MPSIIIA or
MPSIIIB (Héron et al., 2011). Currently there is no cure for
MPSIIIC and existing treatments are aimed solely at controlling the
symptoms of the disease in order to improve the quality of life of
patients and their families.Received 24 February 2016; Accepted 26 July 2016
1Center of Animal Biotechnology and Gene Therapy, Universitat Auto ̀noma de
Barcelona, Bellaterra 08193, Spain. 2Department of Biochemistry and Molecular
Biology, Universitat Auto ̀noma de Barcelona, Bellaterra 08193, Spain. 3Centro de
Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas
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HGSNAT is a lysosomal transmembrane enzymewhose function is
to N-acetylate the terminal α-glucosamine residues of intralysosomal
HS prior to its hydrolysis by α-N-acetylglucosaminidase (Klein et al.,
1978). TheHGSNAT gene is composed of 18 exons and is located on
chromosome 8p11.1 (Fan et al., 2006; Hrěbícˇek et al., 2006). The
cDNA encodes a product of 635 amino acids in length, which
contains 11 transmembrane domains, up to five consensus asparagine-
linked glycosylation sites, a cleavable N-terminal signal peptide of 30
amino acids, and a short eight-amino acid C-terminal domain facing
the cytosol (Fan et al., 2006, 2011; Hrěbícˇek et al., 2006). At present,
66 HGSNAT mutations have been identified, which include 37
missense mutations, 14 splicing mutations, five small deletions, two
gross deletions, five small insertions, one small indel mutation, one
gross insertion and/or duplication and one complex rearrangement
(https://portal.biobase-international.com/hgmd/pro/gene.php?gene=
HGSNAT), and some rare polymorphisms that have no effect on the
activity, processing and targeting of the enzyme (Canals et al., 2011;
Feldhammer et al., 2009a). Although the spectrum of mutations in
individuals with MPSIIIC shows high heterogeneity, some of the
identified mutations have high frequency within certain populations,
such as p.R344C and p.S518F in theNetherlands (Ruijter et al., 2008),
c.525dupT in Portugal (Coutinho et al., 2008; Feldhammer et al.,
2009b), c.852–1G4A in southern Italy (Fedele et al., 2007), c.372–
2A>G in Spain (Canals et al., 2011) and c.234+1G>A in Spanish and
Moroccan individuals with MPSIIIC (Canals et al., 2011; Hrěbícˇek
et al., 2006; Ruijter et al., 2008), suggesting geographical founder
effects. Other mutations, e.g. p.R384*, c.23411G4A, c.49311G4A,
p.R344H and p.S541L, show a relatively high incidence among
individuals with MPSIIIC from different geographical origins,
suggesting a founder effect of an ancient mutation (Fan et al., 2006;
Fedele et al., 2007; Feldhammer et al., 2009b; Hrěbícˇek et al., 2006).
Despite the identification of several MPSIIIC-causing mutations, it
has proven difficult to establish a clear genotype-phenotype
correlation, except e.g. for mutations p.G262R and p.S539C from
two sisters that were associated with an attenuated phenotype (Berger-
Plantinga et al., 2004; Ruijter et al., 2008). In any case, the vast
majority of individuals with MPSIIIC are affected by at least one
missense mutation in or adjacent to transmembrane domains of
HGSNAT, interfering with the proper folding of the enzyme
(Feldhammer et al., 2009a,b).
Several naturally occurring or engineered small and large animal
models of Sanfilippo syndrome have been described in the past few
years (Bhaumik et al., 1999; Ellinwood et al., 2003; Fischer et al.,
1998; Li et al., 1999; Thompson et al., 1992; Yogalingam et al.,
2002), including a rodent model of MPSIIIC (Martins et al., 2015).
These animals have proven invaluable to study the ethiopathology
of MPSIII, and have been used to establish proof-of-concept for the
development of new therapeutic approaches (Crawley et al., 2011;
Duncan et al., 2015; Ellinwood et al., 2011; Fu et al., 2011;
Haurigot et al., 2013; Langford-Smith et al., 2012; Murrey et al.,
2014; Ribera et al., 2015; Sorrentino et al., 2013). Herein, we report
a novel murine model of MPSIIIC that recapitulates the human
disease at biochemical, histological and functional level, with
disease affecting not only the brain but also somatic organs.
RESULTS
Generation of Hgsnat knockout mouse to develop an animal
model for MPSIIIC
Embryonic stem cells (ESCs) with targeted disruption of theHgsnat
gene were obtained and microinjected into C57BL/6J blastocytes
using standard methods. In these cells, successful homologous
recombination of the targeting construct results in expression of the
LacZ gene encoding bacterial β-galactosidase under the control of
the endogenousHgsnat promoter from the targeted alleles (Fig. S1).
Correct targeting was confirmed by Southern blot (data not shown)
and by specific PCR that yielded different band patterns for wild-
type (WT) (Hgsnat+/+), heterozygous (Hgsnat+/−) or homozygous
(Hgsnat−/−) knockout mice (Fig. 1A). There was no indication of
embryonic lethality and at birth HGSNAT-deficient mice were
viable and completely undistinguishable from WT and
heterozygous littermates. No statistical differences were detected
in the body weight at any of the ages analyzed (Fig. S2).
No Hgsnat transcripts could be detected in the kidney of
homozygous Hgsnat−/− male mice by northern blot analysis with a
probe specific for murine Hgsnat (Fig. 1B). This observation was
later confirmed by qRT-PCR in samples obtained from brain and
liver (Fig. 1C). Accordingly, HGSNAT enzymatic activity was
practically undetectable in brain and liver of Hgsnat−/− mice
(Fig. 1D). Heterozygous mice showed reduced Hgsnat expression
and HGSNAT activity (Fig. 1B-D). This lower than normal
enzymatic activity in Hgsnat+/− mice did not alter the content of
GAGs in tissues (data not shown), indicating that half of normal
HGSNAT activity is enough to support normal catabolism of
GAGs. Similar results were obtained in females (Fig. S5A,B).
Fig. 1. Generation of Hgsnat knockout
mouse. (A) Genotyping of wild-type (WT),
heterozygous (Hgsnat+/−) and homozygous
(Hgsnat−/−) mice was performed by PCR
analysis of genomic DNA. The location within
the gene locus of the primers used is indicated
in Fig. S1. The bands of 395 and 329 bp
correspond to WT and mutant alleles,
respectively. (B) Representative northern blot
performed on total RNA extracted from the
kidney of WT, Hgsnat+/− and Hgsnat−/− male
mice and hybridized with a probe specific for
Hgsnat mRNA. (C) Hgsnat mRNA expression
analyzed by qRT-PCR in brain and liver of the
same cohorts with primers and probes as
listed in Materials and Methods; n=4 animals/
group. AU, arbitrary units. (D) HGSNATactivity
in brain and liver of the same cohorts; n=5-7
animals/group. Results are shown as mean±
s.e.m.; ***P<0.001 versus WT by one-way
ANOVA followed by Dunnett post-test.
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Taken together these results demonstrated efficient disruption of the
Hgsnat gene.
Study of Hgsnat gene expression in the CNS and somatic
organs
The design of the targeting construct allows for analysis of the
sites of endogenous Hgsnat expression through detection of
β-galactosidase activity. In toto X-gal staining of the encephalon
of Hgsnat−/−mice showed widespread and strong blue signal of the
reaction product throughout the forebrain and midbrain (Fig. S3,
upper panel and A-C). In general, the pattern of expression was
homogenous and diffuse, e.g. in the neocortex, the piriform lobe
and thalamus (Fig. S3A-C), except for the hippocampus in which
the signal was particularly intense in CA1 and CA3 cells, with lesser
expression detected in the dentate gyrus (Fig. S3B). Lower but
detectable levels of LacZ expression were observed in the
cerebellum, with Purkinje cells evidencing the most intense signal
in this structure (Fig. S3D). The widespread expression of the
Hgsnat gene throughout the CNSwas in agreement with the fact that
the brain is the most affected organ in Sanfilippo syndrome type C
(Kurihara et al., 1996; Martin et al., 1979).
We then evaluated in toto β-galactosidase activity in somatic
organs (Fig. S4). The vast majority of organs analyzed showed
expression ofHgsnat. In the kidney, the cortex stainedmore than the
medulla; in the medullar region, positivity was associated with
tubular structures that converged in the renal pelvis, namely
papillary ducts (Fig. S4A). Very strong staining was observed in the
ureter and, to a lesser degree, in the urinary bladder (Fig. S4A,B). In
contrast, the lungs were practically negative, with minimal staining
of the lobar bronchus (Fig. S4C). When the whole heart was
incubated in X-gal, ventricles showed very weak and diffuse signal
whereas atriums were strongly positive, and so was the pulmonary
trunk (Fig. S4D). When the heart was sectioned to allow
visualization of inner structures, a diffuse staining was observed
in the inner surface of the myocardium of the left ventricle,
particularly in the papillary muscles (Fig. S4E,F). In the transversal
section of the atrium, the tricuspid valve stained strongly positive
(Fig. S4G). The staining of the liver was moderately intense, but the
gallbladder was markedly blue (Fig. S4H,I). The pancreas was
faintly blue throughout (Fig. S4J). The parenchyma of the spleen
was negative to X-gal staining, and the only structures that stained
positive were identified as arterial blood vessels (Fig. S4K).
Similarly, muscle fibers of the gastrocnemius muscle seemed
negative for LacZ expression but muscular arterioles were markedly
positive (Fig. S4L). When X-gal staining was performed on
paraffin-embedded sections of the gastrocnemius muscle, a strong
blue signal was observed in the arterial tunica media of these vessels
(Fig. S4M). Finally, in the reproductive tract, in females the oviduct
stood out as the most positive structure, although the follicles inside
the ovary were also fairly positive (Fig. S4N); in testicles, the
seminiferous tubules stained strongly with X-gal (Fig. S4O).
CNS lysosomal pathology in HGSNAT-deficient mice
Neurological alterations are one of the main features of MPSIIIC
disease (Héron et al., 2011; Malm andMånsson, 2010; Ruijter et al.,
2008). Therefore, we set out to investigate the presence of lysosomal
pathology in the brain of mice with HGSNAT deficiency. Animals
of 2, 12 and 22 months of age were analyzed to evaluate the age of
onset and the progression of the lysosomal pathology affecting the
CNS. HGSNAT-deficient male and female mice showed a
progressive increase in GAG accumulation in all brain regions
analyzed, ranging from 4% to 80% over values observed in healthy
littermates (Fig. 2A; Fig. S5C). In both sexes, the accumulation was
particularly noticeable in the most frontal portions of the brain
(Sections I-III; Fig. 2A; Fig. S5C), in which the excessive storage of
GAG was readily detectable as early as 2 months of age. Consistent
with the observed accumulation of GAGs, immunohistochemical
analysis of brain sections with an antibody reactive to the lysosomal
marker lysosomal associated membrane protein 2 (LAMP2) used as
indicator of the size of the lysosomal compartment revealed a
statistically significant increase in LAMP2+ area in all regions
analyzed in the CNS of both Hgsnat−/− male and female mice
(Fig. 2B; Fig. S5D). Furthermore, signal intensity increased with
age in both sexes, suggesting the distension of the CNS lysosomal
compartment worsened as animals grew.
This result was further confirmed by ultrastructural analysis of the
encephalon by transmission electron microscopy, which showed an
increase in the size of the lysosomal compartment in the cerebral
cortex and cerebellum of HGSNAT-deficient mice (Fig. 3A). At
5 months of age, Hgsnat−/− animals but not WT littermates had
large electrolucent vacuoles that seemed to be lysosomes loaded
with GAGs in the cytoplasm of perineuronal glial cells apposed to
neurons of the cerebral cortex (Fig. 3A, left panels). The juxtaposed
neurons had few or no discernable storage lesions at this age
(Fig. 3A, left panels). In the cerebellum, electrolucent vesicles of
smaller size were detected in the cytoplasm of Purkinje cells in
Hgsnat−/− mice (Fig. 3A, right panels). The content of these
vesicles seemed different from that observed in cortical
perineuronal glial cells (Fig. 3A, right panels). Furthermore, the
cellular pathology observed in Purkinje cells from HGSNAT-
deficient mice affected not only lysosomes but also mitochondria,
which showed significant cristae loss and disorganization of their
inner membrane system (Fig. 3B). Taken together, these data
demonstrate the presence of progressive storage disease in the CNS
of HGSNAT-deficient mice starting from an early age.
Secondary lysosomal pathology in the CNS of HGSNAT-
deficient mice
In LSDs, the loss of activity of a specific lysosomal enzyme results
in the perturbation of normal lysosomal homeostasis, characterized,
amongst other changes, by secondary alteration of other enzymatic
activities and accumulation of additional compounds (Sardiello
et al., 2009). In the brain of HGSNAT-deficient mice, we observed
changes in the activities of several lysosomal enzymes, such as IDS,
SGSH, NAGLU, GALNS, GUSB and β-HEXO (Fig. 3C; Fig. S6).
These changes were detectable as early as 2 months of age and
remained altered in older mice (Fig. 3C; Fig. S6).
Neuroinflammation in the brain of mice deficient in HGSNAT
There is plenty of evidence from animal models (Martins et al.,
2015; Ohmi et al., 2003; Wilkinson et al., 2012) and humans
(Hamano et al., 2008; Kurihara et al., 1996; Tamagawa et al.,
1985) indicating that there is activation of glial cells in all forms of
Sanfilippo syndrome. To investigate if the deficiency in HGSNAT
also caused a neuroinflammatory response in our animal model, we
stained brain sections from 2-, 12- and 22-month-old mice with an
anti-GFAP antibody that specifically recognizes glial fibrillary
acidic protein expressed in activated astrocytes (Eng and Ghirnikar,
1994) and with the lectin BSI-B4, which under our staining
protocol binds to activated microglia (Ribera et al., 2015; Streit and
Kreutzberg, 1987). At the early age of 2 months, Hgsnat−/− mice
of both sexes already showed marked astrocytosis in all brain
regions analyzed (Fig. 4A,B; Fig. S7A,B). The increase in GFAP+
signal remained statistically significant at later time points in all
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Fig. 2. CNS storage pathology in Hgsnat−/−mice. (A) GAG content in different brain regions (sections I-V illustrated in the diagrams above the plot) in WT and
Hgsnat−/−malemice at 2, 12 and 22 months of age; n=4-5 animals/group. Absolute values of CNSGAG content inWTanimals are listed in Table S1. (B) Analysis
of the lysosomal compartment by LAMP2 immunostaining in different brain regions of the same cohorts of animals as in A. HGSNAT-deficient animals showed a
progressive increase in the size of the lysosomal compartment with age. Insets show a magnified region of the main panel. Histograms below the images depict
the corresponding quantification of LAMP2+ signal for each brain region in each group; n=4-5 animals/group. Results are shown as mean±s.e.m.; *P<0.05,
**P<0.01 and ***P<0.001 versus WT by two-tailed t-test for statistical comparison of HGSNAT-deficient mice with their respective controls. Scale bars: 100 µm;
insets, 20 µm.
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Fig. 3. Ultrastructural analysis and evaluation of lysosomal homeostasis in the CNS of HGSNAT-deficient mice. (A) Transmission electron microscopy of
samples from the frontal cortex (left panels) and cerebellum (right panels) of 5-month-oldWTandHgsnat−/−male mice. Large electrolucent vacuoles (red arrows)
were detected in perineuronal glial cells (1) associated with neurons (2) of the frontal cortex in HGSNAT-deficient male mice, whereas smaller vesicles with
seemingly different content were observed in cerebellar Purkinje cells. (B) Representative images of mitochondria found in Purkinje cells of WT and Hgsnat−/−
mice. The mitochondrion from a Hgsnat−/− Purkinje cell shows loss of normal mitochondrial structure and reduced cristae (asterisks). (C) Percentage of WT
activity for a range of lysosomal enzymes analyzed in brain extracts fromWTandHgsnat−/−male animals at 2, 12, and 22 months.Hgsnat−/−mice showed altered
activities of iduronate-2-sulfatase (IDS), N-sulphoglucosamine sulphohydrolase (SGSH), α-N-acetylglucosaminidase (NAGLU), N-acetylgalactosamine-6-
sulfatase (GALNS), β-glucuronidase (GUSB) and β-hexosaminidase (β-HEXO); n=4-5 animals/group. Absolute values of CNS enzymatic activities inWTanimals
are listed in Table S2. Results are shown as mean±s.e.m.; *P<0.05, **P<0.01 and ***P<0.001 by two-tailed t-test for statistical comparison of HGSNAT-deficient
mice with their respective controls. Scale bars: 2 µm in A, 100 µm in B.
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regions, except for the superior colliculus in which significance
was lost in very old animals (Fig. 4A,B; Fig. S7A,B). Similarly,
BSI-B4 staining evidenced strong infiltration with activated
microglia in the brains of Hgsnat−/− male and female mice,
starting at 2 months and worsening with age (Fig. 4C,D;
Fig. S7C,D). Quantification of signal intensity showed
statistically significant increases in the BSI-B4+ area in Hgsnat−/−
animals in all brain regions at all ages (Fig. 4C,D; Fig. S7C,D).
Moreover, in the case of BSI-B4 staining, the progression with age
was much more apparent than for GFAP staining. These results
provide further evidence of progressive pathology in the CNS of
HGSNAT-deficient mice.
Loss of HGSNAT activity causes somatic pathology in mice
Lack of HGSNAT activity (Fig. 1D; Fig. S5B) led to the
accumulation of GAGs in peripheral organs of male and female
mice as early as 2 months of age (Fig. 5A; Fig. S8A). The build-up
of undegraded GAGs was most noticeable in liver, spleen and
kidney (Fig. 5A; Fig. S8A) and, in most organs, was progressive,
showing a considerable increase particularly between 2 and
12 months of age (Fig. 5A; Fig. S8A). This excessive somatic
accumulation of GAGs was accompanied by an expansion of the
lysosomal compartment in male and female Hgsnat−/− mice, as
detected by immunostaining of liver, heart, lung and urinary bladder
tissue sections with an antibody against the lysosomal marker
lysosomal associated membrane protein 1 (LAMP1) (Fig. 5B;
Fig. S8B). As observed for GAG content, in both sexes the size of
the lysosomal compartment seemed to increase with age.
At ultrastructural level, the pattern of enlargement of the
lysosomal compartment in HGSNAT-deficient mice varied
depending on the cell type and organ. In the liver, whereas
hepatocytes showed a large number of small electrolucent vacuoles
in their cytoplasm, Kupffer cells had few but very distended vesicles
(Fig. 6A). Conversely, cells from the proximal tubules of the kidney
showed vesicles of a size similar to those observed in hepatocytes
(Fig. 6A). Ciliated cells from the bronchial tube of the lung and cells
interspersed amongst myocardial cells of the cardiac ventricle had
relatively large storage vesicles, which did not seem to be present in
other cells of the parenchyma of these structures (Fig. 6A). Very
similar observations were made in both sexes (Fig. S9). The
excessive storage of undegraded substrates can give rise to
organomegaly, a common feature of LSDs, including MPSIIIC
(Bartsocas et al., 1979; Héron et al., 2011; Huh et al., 2013; Ruijter
et al., 2008). Hgsnat−/− mice did not show any organomegaly at
2 months of age, but organ weight increased with age to an evident
hepato- and splenomegaly in older mice (Fig. S10A,B). Taken
together, these results provide evidence of severe progressive storage
pathology in peripheral organs of Hgsnat−/− mice of both sexes.
Fig. 4. Astrocytosis andprogressive infiltrationwith activatedmicroglia in the brain ofHgsnat−/−mice. (A) Representative images of the immunostaining of
brain sections with an antibody specific for the astrocyte marker GFAP.WT andHgsnat−/−male micewere analyzed at 2, 12 and 22 months of age. Insets show a
magnified region of themain panel. (B) Histograms represent the percentageGFAP+ area in each brain region analyzed; n=4-5 animals/group. (C) Representative
images of the analysis of microgliosis by staining with BSI-B4 lectin in brain sections from the same cohorts. Microgliosis worsened with age in Hgsnat−/−mice.
(D) Histograms depict the quantification of BSI-B4+ area in each brain region analyzed; n=3-5 animals/group. Results are shown as mean±s.e.m.; **P<0.01,
***P<0.001 by two-tailed t-test for statistical comparison of HGSNAT-deficient mice with their respective controls. Scale bars: 50 µm; insets, 20 µm. Ctx, Cortex;
S., Superior; m, months.
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As previously observed in the CNS, the lack of HGSNAT activity
in liver of knockout mice resulted in secondary alteration of the
activity of lysosomal enzymes involved not only in the degradation
of GAGs (i.e. IDUA, IDS, SGSH, NAGLU, GALNS and GUSB)
but also in the degradation of other macromolecules (i.e. β-HEXO),
indicating a general alteration of normal lysosomal homeostasis
(Fig. 6B; Fig. S10C). In most cases the activity of these enzymes
was increased by several fold over the levels observed in healthy
WT animals from an early age, and the increment was particularly
noticeable for β-HEXO (Fig. 6B; Fig. S10C).
Finally, to assess general health status, we measured several
biochemical parameters, including glucose, aspartate aminotransferase
Fig. 5. Somatic lysosomal pathology in HGSNAT-deficient mice. (A) Quantification of GAG content in somatic organs and tissues from healthy (WT) and
Hgsnat−/− male mice at 2, 12 and 22 months of age. Progressive GAG accumulation was observed in most somatic organs analyzed; n=4-5 animals/group.
Absolute values of somatic tissue GAG content in WT animals are listed in Table S1. (B) Immunostaining against LAMP1 of liver, heart, lung and urinary bladder
tissue sections demonstrating enlargement of the lysosomal compartment in affected male mice. Insets show a magnified region of the main panel. Results are
shown as mean±s.e.m.; **P<0.01 and ***P<0.001 by two-tailed t-test for statistical comparison of HGSNAT-deficient mice with their respective controls. Scale
bars: 50 µm; insets, 10 µm.
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(AST), alanine aminotransferase (ALT), total bilirubin, creatinine and
urea in sera obtained from 2-, 12- and 22-month-old animals. Of these,
ALT and urea showed statistical differences from the values observed
in WT animals (Fig. S10D), suggesting a mild degree of liver and
kidney pathology. Taken together, these data demonstrate that
Hgsnat−/− mice have established disease in somatic organs as early
as 2 months of age, with increased intracellular GAG storage, evident
lysosomal distension and perturbation of normal lysosomal
homeostasis, all of which could affect organ functionality.
Behavioral deficits and shortened lifespan inHgsnat−/−mice
Behavioral disturbances are a hallmark of progressive neurological
diseases such as MPSIIIC (Delgadillo et al., 2013; Héron et al.,
2011; Malm and Månsson, 2010; Ruijter et al., 2008). To test if the
behavior of Hgsnat−/− mice was altered by a lack of HGSNAT,
naïve Hgsnat−/− males of 2, 12 and 22 months of age were
subjected to the open field test, which evaluates the general
locomotor and exploratory activity of mice in surroundings that are
unknown to them (Bailey and Crawley, 2009). At all ages tested,
Fig. 6. Ultrastructural analysis and evaluation of lysosomal homeostasis in somatic organs of HGSNAT-deficient mice. (A) Transmission electron
microscopy of liver, kidney, lung and heart fromWTandHgsnat−/−malemice at 5 months of age demonstrating the enlargement of the lysosomal compartment in
different cells types. Electrolucent vacuoles (red arrows) of different size were detected in hepatocytes and Kupffer cells of the liver, in cells from the proximal
tubules of the kidney, in ciliated cells of the bronchial tubes and in macrophage-like cells in the heart myocardium ofHgsnat−/−mice. (1) Ciliated cells; (2) exocrine
club cells. (B) Activity, as percentage of WT, of the lysosomal enzymes iduronidase (IDUA), iduronate-2-sulfatase (IDS), N-sulphoglucosamine sulphohydrolase
(SGSH), α-N-acetylglucosaminidase (NAGLU), N-acetylgalactosamine-6-sulfatase (GALNS), β-glucuronidase (GUSB) and β-hexosaminidase (β-HEXO)
analyzed in liver extracts of Hgsnat−/−male mice at different ages; n=4-5 animals/group. Absolute values of liver enzymatic activities in WT animals are listed in
Table S2. Results are shown as mean±s.e.m.; *P<0.05, **P<0.01 and ***P<0.001 by two-tailed t-test for statistical comparison of HGSNAT-deficient mice with
their respective controls. Scale bars: 2 µm; insets, 1 µm.
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Hgsnat−/− mice crossed fewer lines and travelled less distance than
WT littermates during the first three minutes of the recording period,
which combined with the observation that Hgsnat−/− mice spent
more time resting, suggested hypoactive behavior (Fig. 7A-C).
Hgsnat−/− mice also took longer to reach the center of the arena,
known to be most stressful zone, and did so on fewer occasions,
spending more time at the border (Fig. 7D-F). Indeed, at 2 months
of age, 28.5% of Hgsnat−/− mice failed to enter the center of the
arena in the first 3 min of recording, whilst all WT did. At 12 and
22 months the percentage of Hgsnat−/− mice that took longer than
3 min to enter the center of the arena for the first time increased to
34% and 68.4%, respectively. Only one of the tested WT animals
failed to visit the center during the first 3 min at 12 months of age,
increasing to 25% in 22-month old animals. Taken together, these
results suggest that Hgsnat−/− mice suffer from anxiety. When the
data corresponding to the recording over a period of 15 min was
analyzed, a few of the statistical differences observed during the first
3 min at 2 and 12 months of age disappeared, including those that
are more representative of locomotor activity, such as total resting
time. This observation argues in favor of anxiety being a strong
component of the behavior observed during the first 3 min of the
test. In animals aged 22 months, the observations made at 15 min
resembled those made after 3 min of recording, evidencing
profound decline in motor functions at this age, which is
compatible with late stage neurodegeneration. These behavioral
alterations were in line with those previously observed by several
other groups in two different mouse models of Sanfilippo disease
(Fraldi et al., 2007; Haurigot et al., 2013; Hemsley and Hopwood,
2005; Lau et al., 2008; Li et al., 1999; McIntyre et al., 2010, 2014;
Ribera et al., 2015).
Finally, the analysis of survival showed a highly statistically
significant reduction in the lifespan of Hgsnat−/−male mice, with a
median survival of 21.2 months compared with 24.6 months for
WT siblings (P=0.0001; Fig. 7G). Similarly, HGSNAT-deficient
females were shorter-lived than WT counterparts (19.7 months and
23 months, respectively, P=0.0008; Fig. S11).
MPSIIIC progressesmoreslowly thanMPSIIIA andMPSIIIB in
rodents
HGSNAT-deficient males (MPSIIIC males) showed behavioral
alterations that reproduced the observations we and others have
previously reported in two other mouse models of Sanfilippo disease,
MPSIIIA and MPSIIIB mice (Fu et al., 2007; Haurigot et al., 2013;
Hemsley and Hopwood, 2005; Hemsley et al., 2009; Lau et al., 2008;
Li et al., 1999; Ribera et al., 2015). The main difference between
the MPSIIIC model and the MPSIIIA and MPSIIIB models was the
Fig. 7. Behavioral deficits and shorter survival of HGSNAT-deficient animals. (A-F) The open field test was performed in naïve-tested WT and Hgsnat−/−
male mice at 2 (n=14-17), 12 (n=22-29) and 22 (n=16-19) months of age. Data correspond to the locomotor and exploratory activity recorded either during the first
3 min or a total of 15 min. Histograms depict the results of the parameters analyzed: (A) total number of lines crossed, (B) total distance travelled, (C) resting time,
(D) time in border, (E) entries in center, and (F) latency to center. Results are represented as mean±s.e.m.; *P<0.05, **P<0.01 and ***P<0.001 by two-tailed t-test
for statistical comparison of HGSNAT-deficient mice with their respective controls. (G) Kaplan–Meier survival analysis in WT (n=33) and Hgsnat−/− (n=22) male
mice. Median survival was 24.6 and 21.2 months, respectively. Kaplan–Meyer estimator followed by log-rank test, P=0.0001.
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progression of the behavioral disturbances; at 22 months of age the
degree of behavioral changes in HGSNAT knockout mice was the
same as in 6-month-old MPSIIIA or MPSIIIB mice (Haurigot et al.,
2013; Ribera et al., 2015). Similarly, the lifespan of HGSNAT-
deficient males and females was shortened but not as dramatically as
that ofMPSIIIA andMPSIIIBmice housed in the same animal facility
(Haurigot et al., 2013; Ribera et al., 2015; Ruzo et al., 2012a,b). To
investigate the reasons for the slower progression of neurological
disease in theMPSIIICmodel,we comparedGAGcontent in different
regions of the encephalon of MPSIIIA, MPSIIIB and MPSIIIC male
mice of the same age (5-6 months) (Fig. 8A). In all regions analyzed,
the accumulation of GAGs was less pronounced in MPSIIIC
mice than in MPSIIIA or MPSIIIB mice, a decrease that reached
statistical significance in most cases, particularly in the most caudal
regions (Sections III, IV and V in Fig. 8A). In agreement with this,
lysosomal-integrated membrane protein 2 (LIMP2) immunostaining
indicated less expansion of the lysosomal compartment in MPSIIIC
mice (Fig. 8B). Interestingly, this milder CNS storage disease
observed in MPSIIIC mice reflected in less infiltration by activated
microglia in the brain of these animals (Fig. 8C). This was particularly
evident when MPSIIIC mice were compared with MPSIIIB mice.
It should be noticed that whereas MPSIIIB and MPSIIIC animals
are full knockouts, MPSIIIA mice arouse from a spontaneous point
mutation and have a small percentage of residual activity
(Bhattacharyya et al., 2001; Bhaumik et al., 1999; Haurigot et al.,
2013; Ruzo et al., 2012a,b).
DISCUSSION
Here we describe a novel animal model with targeted disruption of
the Hgsnat gene. To generate this model we used ESC from the
European Conditional Mouse Mutagenesis Program (EUCOMM)
resource, which has extensively been used to generate hundreds of
knockout mouse mutants for analysis of mammalian gene function
(Hrabe ̌ de Angelis et al., 2015).
HGSNAT-deficient mice showed progressive accumulation of
GAGs and expansion of the lysosomal compartment throughout the
Fig. 8. Comparison of GAG accumulation, CNS lysosomal pathology and brain inflammation in different murine models of MPSIII disease. (A) GAG
content analyzed in different brain regions (sections I-V illustrated in the diagrams above the plot) fromMPSIIIA, MPSIIIB andMPSIIIC mice at 5-6 months of age;
n=4-5 animals/group. Absolute values of CNS GAG content in WT animals from different MPSIII colonies are listed in Table S3. (B) Analysis of the size of the
lysosomal compartment through LIMP2 immunostaining and quantification of LIMP2+ area in different brain regions in the same cohorts of animals as in A; n=3-5
animals/group. (C) Analysis of microgliosis by staining with lectin BSI-B4 in brain tissue sections obtained from the same experimental groups. Histograms depict
the quantification of positive area in each brain region analyzed; n=3-5 animals/group. Results are shown as mean±s.e.m.; *P<0.05, **P<0.01 and ***P<0.001 by
one-way ANOVA followed by Tukey post-test.
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encephalon. At ultrastructural level, and in agreement with
observations made in MPSIIIA and MPSIIIB models (Bhaumik
et al., 1999; Haurigot et al., 2013; Jolly et al., 2007; Ribera et al.,
2015; Ruzo et al., 2012a), cortical neurons showed minimal signs of
storage whereas perineuronal glial cells juxtaposed to them had
large intracytoplasmic vacuoles. Purkinje neurons showed vacuoles
of smaller size in their somas, filled with material of different aspect
from that observed in cortical perineuronal glial cells. Post-mortem
analyzes of human and animal brains have shown secondary storage
in LSDs; GM2 and GM3 gangliosides accumulate, for example, in
MPSIII (Constantopoulos and Dekaban, 1978; Constantopoulos
et al., 1980; Tamagawa et al., 1985). Storage of these compounds in
cellular compartments different from those that accumulate GAGs,
and sometimes even in different cells types (Jolly et al., 2007;
Martins et al., 2015; McGlynn et al., 2004), could account for the
dissimilar aspect of the storage vesicles found in glia and neurons. In
addition, a proportion of the mitochondria of Purkinje cells showed
structural abnormalities. The nature of mitochondrial alterations is
not completely understood but a recent study has postulated that
pathological GM storage in these organelles might be involved
(Martins et al., 2015).
The changes in the activity of lysosomal hydrolases reflected the
perturbation of normal lysosomal physiology by pathological
storage of GAGs, in marked similarity to what we previously
observed in MPSIIIB rodent brains (Ribera et al., 2015). This boost
in lysosomal function is believed to be the consequence of the
activation of the transcription factor EB (TFEB), a master regulator
of lysosomal physiology, in an attempt to counteract pathological
storage (Sardiello et al., 2009). In LSDs, TFEB translocates to the
nucleus and binds to the coordinated lysosomal expression and
regulation (CLEAR) element in the promoter of a number of genes
that control lysosomal biogenesis and enzymatic activities (Ribera
et al., 2015; Sardiello et al., 2009; Settembre et al., 2013). In contrast
to this coordinated upregulation of lysosomal hydrolases, the
activity of GALNS was decreased in the brain of HGSNAT-
deficient mice, possibly resulting from direct inhibition by
accumulated compounds. In vitro studies have suggested that
GALNS is inhibited by HS (Rowan et al., 2013), and keratan sulfate,
one of the substrates of GALNS, is increased in the serum of
Sanfilippo animal models (Rowan et al., 2013) and humans with
Sanfilippo syndrome (Tomatsu et al., 2005).
The brains of HGSNAT-deficient mice also showed astrocytosis
and microgliosis from an early age. This glial response, a hallmark
of human Sanfilippo syndrome (Hamano et al., 2008; Kurihara
et al., 1996; Tamagawa et al., 1985), is believed to be at the
epicenter of disease pathology. In particular, microgliosis, which
can be detected as soon as 10 days after birth in MPSIII mice
(Ausseil et al., 2008), seems to participate in neurodegeneration
through multiple pathological mechanisms including, but not
limited to, the secretion of cytokines and the production of
reactive oxygen species (Archer et al., 2014; Ausseil et al., 2008;
Hamano et al., 2008; Villani et al., 2007; Wilkinson et al., 2012).
At the somatic level, we found hepatomegaly and progressive
accumulation of GAGs in all organs analyzed from HGSNAT-
deficient mice, butmost noticeably in liver, spleen and kidney aswell
as biochemical signs of modest liver and kidney damage. At all ages,
GAG accumulation in the liver and spleen seemed to be slightly less
pronounced in females, which otherwise showed very similar CNS
and somatic phenotypes to HGSNAT-deficient males. The alteration
of lysosomal hydrolases was even more pronounced in liver than in
brain, but followed the same pattern. At the ultrastructural level,
storage lesions seemed to affect specific cell types within each organ.
For example, ciliated cells in the bronchus and cells interspersed in
the myocardium had large quantities of cytoplasmic storage vesicles
but club cells or cardiomyocytes did not.
HGSNAT-deficient males showed behavioral alterations
characterized by anxiety in younger animals and hypoactivity in
later stages of the disease. These observations reproduced those we
and others have previously reported in MPSIIIA and MPSIIIB mice
(Fu et al., 2007; Haurigot et al., 2013; Hemsley and Hopwood,
2005; Hemsley et al., 2009; Lau et al., 2008; Li et al., 1999; Ribera
et al., 2015). The main difference between those models was the
progression of the behavioral disturbances; at 22 months of age
the degree of behavioral changes in HGSNAT knockout mice was
the same as in 6-month-old MPSIIIA or MPSIIIB mice (Haurigot
et al., 2013; Ribera et al., 2015), likely because of milder CNS
storage disease observed in the former. GAG storage, the expansion
of the lysosomal compartment and microgliosis were all less
pronounced in the brains of adult MPSIIIC mice compared with
age-matched animals from our MPSIIIA and MPSIIIB colonies.
Similarly, the lifespan of HGSNAT-deficient males and females
was shortened but not as dramatically as that of MPSIIIA and
MPSIIIB mice housed in the same animal facility (Haurigot et al.,
2013; Ribera et al., 2015; Ruzo et al., 2012a,b). These observations
support the notion of slower progression of MPSIIIC in rodents
when compared with MPSIIIA and MPSIIIB diseases, and are in
agreement with the less aggressive clinical course attributed to
MPSIIIC in humans (Héron et al., 2011; Malm and Månsson, 2010;
Ruijter et al., 2008; Valstar et al., 2008; van de Kamp et al., 1981).
In a study of a large cohort of French individuals affected by
different forms of MPSIII, individuals with MPSIIIC were found to
live significantly longer than individuals with MPSIIIA or MPSIIIB
(Héron et al., 2011). Ruijter et al. (2008) estimated the median
survival of Dutch individuals with MPSIIIC to be 34 years, ranging
from 25 to 48, whereas the median age at death of individuals with
MPSIIIA from Germany has been reported to be 15.2 years (range:
8.5-25.5 years) (Meyer et al., 2007). Indeed, there are several cases
in the literature of individuals with MPSIIIC living into their fourth
and fifth decades (Berger-Plantinga et al., 2004; Héron et al., 2011;
Kurihara et al., 1996; Ruijter et al., 2008).
Interestingly, Martins et al. (2015) described hyperactivity and
reduced anxiety in the open field test in another recently published
mouse model of MPSIIIC, generated by the gene trap technology.
There are important differences in the experimental procedures
followed by each group that could account for this discrepancy.
First, we followed the most standard open field protocol by which
analysis is performed during the first few minutes of recording,
before habituation to the environment occurs (Fraldi et al., 2007;
Haurigot et al., 2013; Hemsley and Hopwood, 2005; Lau et al.,
2008; Li et al., 1999; McIntyre et al., 2010, 2014; Ribera et al.,
2015). Under these conditions, MPSIIIA and MPSIIIB animals
have been described to be hypoactive (Fraldi et al., 2007; Haurigot
et al., 2013; Hemsley and Hopwood, 2005; Lau et al., 2008; Li et al.,
1999;McIntyre et al., 2010, 2014; Ribera et al., 2015), hyperactivity
having been described only temporarily in very young (3-week-old)
MPSIIIAmice that turn hypoactive by 6 weeks of age (Hemsley and
Hopwood, 2005). Moreover, when we analyzed the behavior over a
period of 15 min, a time at which habituation to the environment has
already begun, younger HGSNAT-deficient mice showed identical
behavior to WT animals, but older mice continued to show
hypoactivity, indicating loss of motor functions. In contrast to this
protocol, Martins et al. reported the total outcome after 60 min of
recording, and this could have influenced the type of behavior
evidenced by the test. Secondly, in their manuscript, Martins et al.
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only show the results of the open field test performed in females, in
which statistical significance was reached at 6 and 8 month of age
but disappeared as animals grew older (Martins et al., 2015). The
authors stated that the same trend was observed in male mice,
although in this case statistical difference was reached only at
8 months of age for most parameters. Conversely, we performed the
open field test in HGSNAT-deficient males, as in our experience
with different murine models of MPSIII the results obtained in
females can vary considerably owing to the influence of cyclic
sexual hormones. In both mixed and congenic MPSIIIA mouse
strains, altered locomotor open field activity manifested mostly in
male mice (Hemsley and Hopwood, 2005; Lau et al., 2008), an
observation that authors attributed to the neuroprotective effect of
estrogens (Hemsley and Hopwood, 2005). In addition, despite
having almost identical genetic background, the mouse model
described by Martins and colleagues (C57BL/6NCrl) showed a
considerably reduced lifespan in comparison with ours (C57BL/
6NTac), with most MPSIIIC-affected animals dead by the age of
70 weeks (∼14 months), further emphasizing the impact that
differences in housing conditions, diet and experimental protocols
can have on the phenotype described.
Two previous studies analyzed the profile ofHGSNAT expression
in human samples by northern blot (Fan et al., 2006; Hrěbícˇek et al.,
2006). Although both studies used the same commercial source of
polyA+ RNA extracted from various human tissues, the results were
somewhat different. Whereas Fan et al. (2006) found high levels of
expression in heart, skeletal muscle, liver and kidney, with moderate
expression in brain, small intestine, colon, spleen, and placenta and
low levels in other organs, Hrěbícˇek et al. (2006) reported that heart,
leucocytes, lung, placenta and liver were the sites with the highest
expression, with the lowest expression being observed in the brain.
Taking advantage of the design of our targeting construct, in which
the reporter bacterial protein β-galactosidase is expressed under the
control of the endogenous Hgsnat promoter in the recombined
allele, we performed a thorough anatomical description of the sites
of Hgsnat expression in mice. In toto incubation of tissues and
organs in X-gal solution revealed the encephalon as the organ most
readily stained. Whereas coronal sections of the encephalon showed
intense blue staining after only 4 h of incubation, most somatic
organs needed an overnight incubation to become positive. This
staining pattern is compatible with a disease in which the lack of
enzymatic activity results mostly in neurological manifestations, but
contradicts previous studies in WT mice in which the highest levels
of HGSNAT activity were reported for spleen and lungs, and brain
showed much lower activity – ∼sixfold lower than spleen – and in
the same range as liver (Martins et al., 2015). Of note was the
finding that splenocytes were negative for β-galactosidase activity
and only blood vessels stained blue in the spleen. This was
somewhat unexpected as splenomegaly is a frequent sign of
Sanfilippo syndrome (Valstar et al., 2008, 2010a,b), and HGSNAT-
deficient mice accumulated large amounts of GAGs in this organ
(sixfold higher than WT). To a lesser degree, a similar observation
was made in the liver. Given that hepatomegaly is not an uncommon
finding in affected individuals (Buhrman et al., 2014; Cleary and
Wraith, 1993; Héron et al., 2011; Huh et al., 2013; Ruijter et al.,
2008; Valstar et al., 2008) we expected significant staining of this
organ, almost in the same range as that observed in the brain.
However, after an overnight incubation in X-gal solution there was
only faint staining of hepatocytes and the only intensely blue
structures were identified as blood vessels. Despite this weak LacZ
expression in hepatocytes, the content of GAGs in the liver of
HGSNAT-deficient animals was almost tenfold higher than in WT
littermates, and at ultrastructural level, hepatocytes and, specially,
Kupffer cells, showed a large number of electrolucent vesicles, an
observation previously made in subjects affected by MPSIIIC
(Kurihara et al., 1996). All tissues analyzed were cut across to
ensure penetration of the X-gal reagent. Although technical
limitations cannot be completely ruled out, these apparent
discrepancies suggest intriguing pathophysiological mechanisms
of disease. It might be the case that under normal circumstances the
liver and spleen produce enough HGSNAT protein to cope with the
normal turnover of GAGs in these tissues. However, in a disease
state these organs might participate in the clearance of GAGs from
the circulation, as GAG levels are considerably increased in the
blood and urine from individuals with all forms of MPS (de Ruijter
et al., 2012, 2013; Pievani et al., 2015; Rowan et al., 2013; Sifuentes
et al., 2007; Tomatsu et al., 2005). That macrophages might buffer
storage overload by uptake of GAGs from the interstitial space or
blood was proposed a few years ago to justify the presence of large
storage vesicles in glial cells juxtaposed to neurons with very little
evidence of storage disease, or the presence of foamy macrophages
in almost all tissues of MPS animal models (Jolly et al., 2007).
Alternatively, the rate of turnover of GAGs in liver and spleen might
be higher than in other tissues, hence the lack of enzymatic activity
has a much bigger impact in terms of substrate accumulation.
Finally, another plausible explanation to such a pronounced
increase in GAG content in organs that do not seem to express
Hgsnat at high levels could be that the accumulation of HS and
derivatives causes inhibition of lysosomal enzymes involved in the
degradation of other GAGs. In other words, the GAG quantified by
the unspecific Blyscan method is a GAG different from HS. As
mentioned before, a recent report suggested that in Sanfilippo
syndrome, the enzyme GALNS might be inhibited by HS and
heparin (Rowan et al., 2013) resulting in secondary accumulation of
keratan sulfate in humans (Tomatsu et al., 2005). Supporting this
hypothesis we found decreased activity of GALNS in the liver of
HGSNAT-deficient mice.
In summary, the disruption of the Hgsnat gene in mice led to
appearance of a wide range of signs of CNS and somatic pathology
that recapitulate human MPSIIIC at biochemical, histological and
functional level (Delgadillo et al., 2013; Héron et al., 2011; Huh
et al., 2013; Kurihara et al., 1996; Malm andMånsson, 2010; Martin
et al., 1979; Turki et al., 1989). This new animal model should prove
a valuable tool for the study of the pathophysiology of the disease as
well as for the development of novel therapeutic approaches.
Although mice fully deficient in HGSNAT represent the most severe
phenotype of MPSIIIC disease, any evidence of therapeutic efficacy
demonstrated in this model would be encouraging for clinical
translation to human individuals with a broader clinical spectrum.
MATERIALS AND METHODS
Animals
C57BL/6N-A/a ESC clones carrying a reporter (LacZ gene) tagged insertion
in the murine Hgsnat gene [Hgsnattm1a(EUCOMM)Wtsi] available through
the International Mouse Phenotyping Consortium (IMPC, www.
mousephenotype.org) were obtained. The clone EPD0485_4_B08 was
microinjected in C57BL/6J blastocytes in the Transgenic Animal Unit of the
Center of Animal Biotechnology and Gene Therapy (CBATEG) at
Universitat Autònoma de Barcelona (UAB), and the resulting male
chimeras were bred with C57BL/6NTac females to generate Hgsnat
knockout offspring, which were 100% C57BL/6NTac. Genotyping was
performed by PCR analysis using both locus-specific and LacZ cassette-
specific primers Hgsnat-Fw: 5′-ACA AATACC TTG TTC CAT TCC GCC
A-3′; Internal-Rev: 5′-GCC ACC CAA CTG ACC TTG GGC-3′; Hgsnat-
Rev: 5′-ACT GCA CCT CTG CTC CAG TTA GA-3′. Bands of 395 or
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329 bp were obtained for WT or knockout alleles, respectively.
Homozygous mutant mice (Hgsnat−/− mice) were obtained by mating
heterozygous littermates. Mice were fed ad libitum with standard diet
(Harlan-Teklad) and maintained under a light-dark cycle of 12 h. All
experimental procedures were approved by the Ethics Committee for
Animal and Human Experimentation of UAB.
Sample collection
Mice were anesthetized (100 mg/kg ketamine and 10 mg/kg xylazine),
blood was extracted by cardiac puncture, and animals were intracardially
perfused with 12 ml PBS to clear remaining blood from tissues. Brain and
somatic tissues were collected and kept at −80°C or fixed in formalin. For
the analysis of LacZ expression, animals were anticoagulated by
intraperitoneal injection of 500 IU of heparin (Hospira) prior to anesthesia.
RNA analysis
For northern blot analysis, total RNA was obtained from kidneys
homogenized in Tripure Isolation Reagent (Roche) and purified following
manufacturer’s instructions. 20 μg of RNA were electrophoresed in 1%
denaturing agarose gels, transferred to nylon membranes, and blots
hybridized with 32P-labeled Hgsnat cDNA probe labeled by random
oligopriming (GE Healthcare). For qRT-PCR analysis, total RNA from
brain or liver was purified using RNeasy Mini Kit (Qiagen), and 1 μg was
retrotranscribed with Transcriptor First Strand cDNA Synthesis Kit
(Roche). Quantitative PCR was performed in a Light Cycler® 480
(Roche) using Light Cycler® 480 SybrGreen I Master (Roche) and
primers specific for Hgsnat (forward: 5′-CGG CGT TCT TCT GCG
AAC CG-3′; reverse: 5′-GGT CGG CCA CAG TCA GTC CG-3′) and
normalized to the expression of mouse Rplp0 gene (forward: 5′-GGC CCT
GCACTC TCG CTT T-3′; reverse: 5′-TGC CAG GAC GCG CTT GT-3′).
X-gal staining
Tissues were dissected and fixed in 4% paraformaldehyde (Sigma) for 1.5 h
and incubated protected from light at 37°C in X-gal (5-bromo-4-chloro-3-
indoyl-β-d-galactopyranoside) solution [0.4 mg/ml X-gal (Sigma), 200 mM
potassium ferrocyanide, 200 mM potassium ferrocyanate, 1 M MgCl2
diluted in PBS]. Coronal sections of the encephalon were incubated for 4 h,
whereas sagittal sections and somatic tissues were incubated overnight. To
stop the reaction, X-gal solution was removed and tissues werewashed twice
with PBS. Samples were kept in 10% neutral buffered formalin at 4°C until
images were captured under a SMZ1000 zoom stereomicroscope (Nikon).
Activity of lysosomal enzymes
Brain and liver samples were sonicated in 250 and 500 µl of water,
respectively. Homogenized tissues were clarified by centrifugation and
supernatants were recovered to assay enzyme activities using
4-methylumbelliferone-derived ﬂuorogenic substrates based on standard
protocols (Hopwood et al., 1979; Ribera et al., 2015; Voznyi et al., 1993;
Zhao et al., 1991). HGSNAT activity was assayed in 90 µg of protein extracts
incubated with 3 mM 4-methylumbelliferyl-β-D-glucosamine (Moscerdam
Substrates) supplemented with 12 mM acetyl coenzyme A (Sigma) for 3 h at
37°C. Iduronidase (IDUA) activity was assayed in 15 µg of tissue protein
extracts incubated for 1 h at 37°C with 4-methylumbelliferyl α-L-iduronide
2 mM (Glycosynth) at pH 3.5. For iduronate-2-sulfatase (IDS) activity
quantification, 15 µg of total protein were incubated with 1.25 mM
4-methylumbelliferyl-α-L-iduronide-2-sulfate (Moscerdam Substrates) for
4 h at 37°C followed by a second incubation with a pool of
lysosomal enzymes from bovine testis (LEBT-M2, Moscerdam Substrates)
for 24 h at 37°C. N-sulfoglucosamine sulfohidrolase (SGSH) and
N-acetylgalactosamine-sulfate (NAGLU) activities were analyzed as
previously described (Haurigot et al., 2013; Ribera et al., 2015). GALNS
activity was assayed in 10 µg of total protein with a first incubation step with
10 mM 4-methylumbelliferyl β-D-galactopyranoside-6-sulfate (Toronto
Research Chemicals) for 17 h at 37°C followed by a second incubation
with β-galactosidase (Sigma) for 2 h at 37°C. β-hexosaminidase (β-HEXO)
was assayed in 0.4 µg of protein at pH 4.5 for 1 h at 37°C with 5 mM
4-methylumbelliferyl N-acetyl-β-D-glucosaminide (Sigma). For α-N-
acetylglucosaminidase (GUSB), activity was assayed in 15 µg (brain) or
5 µg (liver) of protein incubated for 1 h with 2 mM 4-methylumbelliferyl-β-
D-glucuronide (Sigma) at pH 4.8 and 37°C. After stopping each enzymatic
reaction by increasing the pH, the released fluorescence was measured with a
FLx800 fluorimeter (BioTek Instruments). Results were calculated as
nanomoles of substrate cleaved per hour per mg of protein quantified by
Bradford assay (Bio-Rad), and then presented as a percentage of the activity of
the WT, which was set to 100%.
GAG quantification
Tissues were weighed and digested overnight in 0.2 mg/ml proteinase K
solution. Extracts were centrifuged and supernatants were clarified by
filtration in 0.22 μm microporous membrane-containing filters (Ultrafree
MC, Millipore). GAG content was determined using the Blyscan sulfated
glycosaminoglycan kit (Biocolor) using chondroitin 4-sulfate as standard
and was normalized to wet tissue weight. Owing to the inherent technical
variability of the assay, the GAG content of WT animals at each age was set
to 1 to allow comparison of data obtained at different points in time.
Histology
Formalin-fixed, paraffin-embedded tissue sections were incubated
overnight at 4°C with rat anti-LAMP1 (SC-19992, Santa Cruz
Biotechnology, 1:100), rat anti-LAMP2 (ab13524, Abcam, 1:500), rabbit
anti-LIMP2 (NB400; Novus Biologicals, 1:100), rabbit anti-GFAP (Z0334,
Dako Cytomation, 1:1000) and BSI-B4 lectin (L5391, Sigma, 1:100). For
bright-field immunostaining, biotinylated rabbit anti-rat IgG (E0467, Dako,
1:300) and biotinylated goat anti-rabbit IgG (31820, Vector Laboratories,
1:300) were used as secondary antibodies. Bright-field sections were stained
with 3,3-diaminobenzidine (Sigma) and counterstained with haematoxylin.
Images were obtained with an Eclipse 90i optical microscope (Nikon).
LIMP2, LAMP2, GFAP and BSI-B4 signals were quantified with the NIS-
Elements Advanced Research 2.20 software (Nikon) in 3-5 20× images of
each brain region of each animal using the same signal threshold settings for
all images. The percentage positive area of each image was then calculated.
Electron microscopy
Frontal cortex, cerebellum, liver, lung, heart and kidney were processed for
transmission electronmicroscopy as previously described (Ruzo et al., 2012a)
and visualized with a H-7000 transmission electron microscope (Hitachi).
Open field test
Animals were always analyzed between 9:00 A.M. and 2:00 P.M., to
minimize influence of circadian cycles. After placing the mouse in the corner
of a brightly lit chamber (41×41×30 cm) divided in three squared concentric
regions (center, 14×14 cm; periphery, 27×27 cm; and border, 41×41 cm),
movements were recorded with a video-tracking system (SmartJunior v3,
Panlab). Motor and exploratory activities were evaluated during the first three
minutes, except for latency to center, which was recorded over 15 min, as
severalMPSIIICmice failed to enter the arena during the first 3 min of the test.
Metabolite analysis
ALT, AST, total bilirubin, creatinine, urea and glucose were measured in
serum samples by spectrophotometry with a CobasMira Analyzer (Roche) by
the Veterinary Clinical Biochemistry Lab of the Veterinary School at UAB.
Statistical analysis
Results are expressed as mean±s.e.m. Statistical comparisons were made with
either unpaired t-test two-tailed or one-way analysis of variance (ANOVA).
Multiple comparisonsweremade usingDunnett or Tukey post-tests. Statistical
significance was considered if P<0.05. The Kaplan–Meier estimate was
applied to survival analysis, followed by log-rank test for comparisons.
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L., Hartmannová, H., Ivánek, R., Čıž́ková, A., Poupětová, H. et al. (2006).
Mutations in TMEM76* cause mucopolysaccharidosis IIIC (Sanfilippo C
syndrome). Am. J. Hum. Genet. 79, 807-819.
Huh, H. J., Seo, J. Y., Cho, S. Y., Ki, C.-S., Lee, S.-Y., Kim, J.-W., Park, H.-D. and
Jin, D.-K. (2013). The first Korean case of mucopolysaccharidosis IIIC (Sanfilippo
syndrome type C) confirmed by biochemical and molecular investigation. Ann.
Lab. Med. 33, 75-79.
Jolly, R. D., Johnstone, A. C., Norman, E. J., Hopwood, J. J. and Walkley, S. U.
(2007). Pathology of mucopolysaccharidosis IIIA in Huntaway dogs. Vet. Pathol.
44, 569-578.
Klein, U., Kresse, H. and von Figura, K. (1978). Sanfilippo syndrome type C:
deficiency of acetyl-CoA:alpha-glucosaminide N-acetyltransferase in skin
fibroblasts. Proc. Natl. Acad. Sci. USA 75, 5185-5189.
Kresse, H. andNeufeld, E. F. (1972). The Sanfilippo A corrective factor. Purification
and mode of action. J. Biol. Chem. 247, 2164-2170.
Kresse, H., Paschke, E., von Figura, K., Gilberg, W. and Fuchs, W. (1980).
Sanfilippo disease type D: deficiency of N-acetylglucosamine-6-sulfate sulfatase
required for heparan sulfate degradation. Proc. Natl. Acad. Sci. USA 77,
6822-6826.
Kurihara, M., Kumagai, K. and Yagishita, S. (1996). Sanfilippo syndrome type C: a
clinicopathological autopsy study of a long-term survivor. Pediatr. Neurol. 14,
317-321.
Langford-Smith, A., Wilkinson, F. L., Langford-Smith, K. J., Holley, R. J.,
Sergijenko, A., Howe, S. J., Bennett, W. R., Jones, S. A., Wraith, J. E., Merry,
C. L. R. et al. (2012). Hematopoietic stem cell and gene therapy corrects primary
neuropathology and behavior in mucopolysaccharidosis IIIA mice. Mol. Ther. 20,
1610-1621.
Lau, A. A., Crawley, A. C., Hopwood, J. J. and Hemsley, K. M. (2008). Open field
locomotor activity and anxiety-related behaviors in mucopolysaccharidosis type
IIIA mice. Behav. Brain Res. 191, 130-136.
Li, H. H., Yu, W.-H., Rozengurt, N., Zhao, H.-Z., Lyons, K. M., Anagnostaras, S.,
Fanselow, M. S., Suzuki, K., Vanier, M. T. and Neufeld, E. F. (1999). Mouse
model of Sanfilippo syndrome type B produced by targeted disruption of the gene
encoding alpha-N-acetylglucosaminidase. Proc. Natl. Acad. Sci. USA 96,
14505-14510.
Malm, G. and Månsson, J.-E. (2010). Mucopolysaccharidosis type III (Sanfilippo
disease) in Sweden: clinical presentation of 22 children diagnosed during a 30-
year period. Acta Paediatr. 99, 1253-1257.
Martin, J. J., Ceuterick, C., Van Dessel, G., Lagrou, A. and Dierick, W. (1979).
Two cases of mucopolysaccharidosis type III (Sanfilippo). An
anatomopathological study. Acta Neuropathol. 46, 185-190.
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